Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers
Publication Date: July 14, 2020
Key Points
Key Points
- Chemotherapy-induced neuropathy (CIPN) is a serious clinical problem caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib.
- No agents are recommended for the prevention of CIPN.
- Duloxetine is the only agent that has appropriate evidence to support its use, but the amount of benefit from duloxetine is limited.
- Therefore, prevention and minimizing risk are the primary objectives.
- Because patients with CIPNBecause patients with CIPNBecause patients with CIPN can have balance troubles and a higher chance of falling, it is reasonable to consider physical and/or occupational therapy approaches for patients with such CIPN-related disabilities.
Prevention
...Prevent...
...Prevent...
...n 1.1Clinicians should assess the...
...1.2Clinicians should NOT offer, and sho...
...ion 1.3Outside the context of a clinical...
...ion 1.4Clinicians should NOT offer the follow...
Treatment
...Treatment
...Treatme...
....1Clinicians should assess, and discuss with pat...
...Treatment...
...ommendation 3.1For cancer patients experiencin...
...commendation 3.2Outside the context of a...
Summary of Recommendations
...ary of Recommendations Intervent...